Verena Köberle

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.1kcitations47works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(24), MicroRNA in disease regulation(10), Hepatocellular Carcinoma Treatment and Prognosis(7), Cancer Research and Treatments(6), Epigenetics and DNA Methylation(5)

Publications47 total

Supplementary Table S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Fig. S3 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Fig. S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Fig. S3 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Data from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Information from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Information from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Fig. S2 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Data from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Fig. S2 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Table S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Fig. S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
2023Open Access
Supplementary Figure S2 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
2023Open Access
Supplementary Figure S1 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
2023Open Access
Supplementary Figure S4 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
2023Open Access
Data from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
2023Open Access
Supplementary Figure S3 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
2023Open Access
Supplementary Figure S1 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
2023Open Access
Supplementary Figure S3 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
2023Open Access
Supplementary Figure S4 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Albrecht Piiper(47), Stefan Zeuzem(43), Oliver Waidmann(43), Bernd Kronenberger(41), Thomas Pleli(33), Christian Schmithals(32), Bianca Kakoschky(28), Ahmed Atef Ibrahim(25), Horst‐Werner Korf(25), Fabian Finkelmeier(22), Andreas Weigert(15), Rolf Marschalek(15), Otto Kollmar(14), Scarlett Nitsch(14), Tobias Schmid(14), Hüdayi Korkusuz(13), Thomas J. Vogl(13), Erik Kowarz(13), José M. Arencibia(12), Eduardo Alonso Augusto(11)